ELI LILLY & Co
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $65.2 | $45.0 | $34.1 | $28.5 | $28.3 |
| Net income | $20.6 | $10.6 | $5.2 | $6.2 | $5.6 |
| Balance Sheet | |||||
| Total debt | $42.5 | $33.6 | $25.2 | $16.2 | $16.9 |
| Cash Flow Statement | |||||
| Free cash flow | $9.0 | $3.8 | $0.8 | $5.7 | $6.1 |
| Dividends | $5.4 | $4.7 | $4.1 | $3.5 | $3.1 |
| Share repurchases | $4.1 | $2.5 | $0.8 | $1.5 | $1.2 |
Shares outstanding 941.4M · Free float 90.1%
Annual filing data through FY ended December 31, 2025; float as of September 14, 2026.
Coverage
September 23, 2026
Biotech Pipeline
Ulcerative colitis: compare the treatment setting before comparing remission
September 23, 2026
Biotech Pipeline
Tirzepatide: an approved dual agonist as a reference point
September 23, 2026
Biotech Pipeline
Retatrutide: Phase 3 results do not yet equal an approval
September 23, 2026
Biotech Pipeline
Orforglipron: oral treatment has crossed the approval boundary
September 23, 2026
Biotech Pipeline
Obesity development: mechanisms and treatment patterns, not a league table
September 23, 2026
Biotech Pipeline
Mirikizumab: induction and maintenance form one approval story